Navigation Links
Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
Date:1/28/2013

ittel zu entwickeln", erklärte Paul Bosse , Präsident und Chief Executive Officer von Charleston . „Ich bin stolz auf das Charleston-Team, insbesondere auf die wichtige Rolle, die es bei der Herstellung von Medikamenten, in regulatorischen Angelegenheiten und im Projektmanagement gespielt hat, ebenso auf Dr. Schachtels Team von weltweit renommierten wissenschaftlichen Beratern und klinischen Forschern, und die neuen Studieninstrumente, die Dr. Schachtel zur Messung von Übelkeit entwickelt hat. CL-108 ist einzigartig", fügte Bosse hinzu, „da es das einzige kommerzielle Produkt ist, das eine brechhemmende Wirkung mit einem Opioid zur Behandlung von mäßigen bis schweren Schmerzen kombiniert und so opioidinduzierte Übelkeit oder Erbrechen (OINV) deutlich mindert oder in vielen Fällen auch verhindert. Übelkeit und Erbrechen sind die häufigsten und besonders belastenden Nebenwirkungen von Opioiden und haben einen erheblichen Einfluss auf das Leben der Patienten und die Ärzte, die diese Patienten behandeln. Das Aufzeigen der vielen Vorteile eines Opioids mit weniger OINV in dieser Phase-3-Studie wird nicht nur die Vermarktung von CL-108, sondern auch die weitere Entwicklung anderer Charleston-Produkte, die jetzt im Labor sind, fördern. Mit seiner umfangreichen Pipeline will Charleston verschiedene Medikamente für Patienten mit Schmerzen ohne die unangenehmen Symptome von Übelkeit und Erbrechen, die von derzeit verfügbaren starken Analgetika verursacht werden, herstellen."

Informationen zu Charleston Laboratories, Inc.

Charleston Laboratories, Inc. ist ein Pharmaunternehmen, das sich auf die Erforschung und Entwicklung neuartiger Schmerzmittel konzentriert, die Übelkeit und Erbrechen, die beiden schwersten Nebenwirkungen opiumhaltiger Schmerzmittel und anderer Schmerzerkrankungen, verhindern oder deutlich redu
'/>"/>

SOURCE Charleston Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
2. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
3. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
4. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
5. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
6. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
7. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
8. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Phase 3 Topical Drug for Raynauds Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") ... for its Telestroke and Teleneurology services. Dr. Ricardo ... commented, "We are extremely proud that our quality of ... we continue to provide lifesaving support and continuity of ... hospitals throughout the United States ." ...
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... 2014  Express Scripts (NASDAQ: ESRX ) ... Scripts Medicare ® Prescription Drug Plans (PDP) will ... WAG ) (NASDAQ: WAG ), ... support  for their Medicare dollars. Medicare beneficiaries ... or Choice plans for 2015 can ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... The U.S. Food and Drug Administration today announced ... Centers of Excellence in Regulatory Science and Innovation (CERSI). ... centers, which will be located at the University of ... and training needed to modernize and improve the ways ...
... Preserve Community Pharmacy Access NOW! (PCPAN) coalition ... Americans from increased costs and decreased access to quality ... Scripts Inc. and Medco Health Solutions Inc., two pharmacy ... on the coalition,s website, outlines the negative impact of ...
Cached Medicine Technology:FDA Invests $2 Million in Partnerships Through Centers of Excellence in Regulatory Science and Innovation 2Nationwide Coalition Issues 'Call To Action' To Stop Express Scripts/Medco Merger 2
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Scientists at ... three drugs that target immune system proteins has the ... has just posted details of the new study on ... now. , Researchers in the UWA School of ... anti-CTLA-4 drugs to mice with mesothelioma with promising results. ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... journal Science that a team of Californian researchers have claimed ... plays an important role in making microscopic worms live longer//. ... equation, the longer you live, the greater your chances of ... is believed that a key element in determining whether a ...
... needs no treatment. Infants aging a few days may get baby ... ,It appears as red or white bumps/spots, from the stage ... infant. // Baby acne typically occurs on the face and chest. ... ointments or creams when it typically appears on face and chest ...
... in the June 2006 issue of the International Journal ... American Society //for Therapeutic Radiology and Oncology, says that ... partial radiation for the breast in order to combat ... ,A seroma is retention of fluid in ...
... up four super speciality hospitals in four zones of the ... covered under its scheme//. ,'These facilities will be ... Mumbai or Pune,' ESI director general Ramesh Inder Singh said ... be totally new ones or existing ESI hospitals would be ...
... latest cookbook by Britain-based celebrity chef Mridula Baljekar, has ... Asian Cuisine Cookbook' category//. ,Baljekar, who runs the ... the award at a star-studded ceremony in Kuala Lumpur, ... ,'I am absolutely overwhelmed and highly honoured ...
... and sexual dysfunction may find Viagra a good option ... express improved sexual enjoyment, orgasm and a less painful ... sexual dysfunction caused by vaginal dryness, and several other ... University of Catania in Italy, have said that the ...
Cached Medicine News:
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
...
...
Lacrimal Cannula, Straight, Stepped DownSize: 19g x 1-1/2"....
Medicine Products: